Herpes Zoster Vaccines

被引：97

作者：

Harbecke, Ruth ^{[1
,2
]}

Cohen, Jeffrey, I ^{[3
]}

Oxman, Michael N. ^{[1
,2
,4
]}

机构：

[1] Dept Vet Affairs VA San Diego Healthcare Syst, San Diego, CA USA

[2] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA

[3] NIAID, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[4] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2021年 / 224卷

关键词：

herpes zoster; zoster vaccine; live attenuated Oka varicella-zoster vaccine; recombinant zoster vaccine; SUBUNIT VACCINE; SAFETY; EFFICACY; ADULTS;

D O I：

10.1093/infdis/jiab387

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Herpes zoster (HZ) affects approximately 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age. The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Merck]) and an adjuvanted VZV glycoprotein E (gE) subunit vaccine (recombinant zoster vaccine [RZV]; SHINGRIX [GlaxoSmithKline]) are licensed for the prevention of HZ and PHN in healthy older adults. The safety and efficacy of both vaccines has been demonstrated in clinical trials in immunocompetent adults and in selected immunocompromised persons and persons with immune-mediated diseases. Numerous real-world effectiveness studies have confirmed the safety and effectiveness of both ZVL and RZV. Recombinant zoster vaccine (RZV) is more effective for prevention of HZ than ZVL. Recombinant zoster vaccine is nonreplicating and is thus safe in immunocompromised persons. Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.

引用

页码：S429 / S442

页数：14

共 15 条

[1] Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy
Benson, Constance A.
Andersen, Janet W.
Macatangay, Bernard J. C.
Mailliard, Robbie B.
Rinaldo, Charles R., Jr.
Read, Sarah
Bozzolo, Dawn R.
Purdue, Lynette
Jennings, Cheryl
Keefer, Michael C.
Glesby, Marshall
Tebas, Pablo
Russell, Amy Falk
Martin, Jason
Annunziato, Paula
Popmihajlov, Loran
Lennox, Jeffrey L.
[J]. CLINICAL INFECTIOUS DISEASES, 2018, 67 (11) : 1712 - 1719
[2] Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
Berkowitz, Elchonon M.
Moyle, Graeme
Stellbrink, Hans-Juergen
Schuermann, Dirk
Kegg, Stephen
Stoll, Matthias
El Idrissi, Mohamed
Oostvogels, Lidia
Heineman, Thomas C.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (08) : 1279 - 1287
[3] Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory
Coplan, PM
Schmader, K
Nikas, A
Chan, ISF
Choo, P
Levin, MJ
Johnson, G
Bauer, M
Williams, HM
Kaplan, KM
Guess, HA
Oxman, MN
[J]. JOURNAL OF PAIN, 2004, 5 (06) : 344 - 356
[4] Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L.
Lal, H.
Kovac, M.
Chlibek, R.
Hwang, S. -J.
Diez-Domingo, J.
Godeaux, O.
Levin, M. J.
McElhaney, J. E.
Puig-Barbera, J.
Abeele, C. Vanden
Vesikari, T.
Watanabe, D.
Zahaf, T.
Ahonen, A.
Athan, E.
Barba-Gomez, J. F.
Campora, L.
de Looze, F.
Downey, H. J.
Ghesquiere, W.
Gorfinkel, I.
Korhonen, T.
Leung, E.
McNeil, S. A.
Oostvogels, L.
Rombo, L.
Smetana, J.
Weckx, L.
Yeo, W.
Heineman, T. C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11) : 1019 - 1032
[5] Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Dagnew, Alemnew F.
Ilhan, Osman
Lee, Won-Sik
Woszczyk, Dariusz
Kwak, Jae-Yong
Bowcock, Stella
Sohn, Sang Kyun
Rodriguez Macias, Gabriela
Chiou, Tzeon-Jye
Quiel, Dimas
Aoun, Mickael
Navarro Matilla, Maria Belen
de la Serna, Javier
Milliken, Samuel
Murphy, John
McNeil, Shelly A.
Salaun, Bruno
Di Paolo, Emmanuel
Campora, Laura
Lopez-Fauqued, Marta
El Idrissi, Mohamed
Schuind, Anne
Heineman, Thomas C.
Van den Steen, Peter
Oostvogels, Lidia
[J]. LANCET INFECTIOUS DISEASES, 2019, 19 (09) : 988 - 1000
[6] Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Dooling, Kathleen L.
Guo, Angela
Patel, Manisha
Lee, Grace M.
Moore, Kelly
Belongia, Edward A.
Harpaz, Rafael
[J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (03): : 103 - 108
[7] The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults
Harpaz, Rafael
Leung, Jessica W.
[J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (02) : 341 - 344
[8] Hesse EM, 2019, MMWR-MORBID MORTAL W, V68, P91, DOI 10.15585/mmwr.mm6804a4
[9] NATURE OF HERPES ZOSTER - A LONG-TERM STUDY AND A NEW HYPOTHESIS
HOPESIMPSON, RE
[J]. PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1965, 58 (01): : 9 - +
[10] Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, Himal
Cunningham, Anthony L.
Godeaux, Olivier
Chlibek, Roman
Diez-Domingo, Javier
Hwang, Shinn-Jang
Levin, Myron J.
McElhaney, Janet E.
Poder, Airi
Puig-Barbera, Joan
Vesikari, Timo
Watanabe, Daisuke
Weckx, Lily
Zahaf, Toufik
Heineman, Thomas C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (22) : 2087 - 2096

← 1 2 →